Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients

Am J Hematol. 2024 Jul;99(7):1437-1440. doi: 10.1002/ajh.27349. Epub 2024 May 7.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antigens, CD19* / immunology
  • Cancer Vaccines / therapeutic use
  • Dendritic Cells* / immunology
  • Humans
  • Immunotherapy, Adoptive* / methods
  • Middle Aged
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Receptors, Chimeric Antigen / immunology
  • Recurrence
  • Young Adult

Substances

  • Antigens, CD19
  • Cancer Vaccines
  • Receptors, Chimeric Antigen

Associated data

  • ClinicalTrials.gov/NCT03291444